When a single drop of Tafflotan was applied to the conjunctiva of each eye overnight for eight days, the concentration content of tafluprost acid in the serum was minimal and the same - both on the first day and on the eighth day of the drug use.
The limiting concentration indices in the serum were detected 10 minutes after the application of the solution and decreased even before the completion of the first 60 minutes. The average concentration limit was the same on the first and on the eighth day, indicating an equivalent content of the medication during the first week of treatment.
Clinically significant differences in the systemic bioavailability of Taflotan preparations with and without a preservative have not been recorded.
There were no specific features in the distribution of the labeled solution in the iris and ciliary body: this indicates a small affinity for the pigmentary substance melanin. During experiments that were performed using autoradiography, the maximum radioactivity was found in the cornea, eyelids, sclera, and iris. Outside the eye organ, radioactivity spread through the lacrimal apparatus, the upper sky, esophagus and digestive system, kidneys, and liver.
The binding of a metabolite with a plasma protein was 99% (with a concentration of a metabolite of 500 ng per ml).
Metabolism is performed by methods of glucuronidation or β-oxidation.
Excretion of Taflotan occurs to a lesser extent through the kidneys (up to 38%) and more to the calves (up to 58%).